ATE261317T1 - Radioaktiv markierte annexine - Google Patents

Radioaktiv markierte annexine

Info

Publication number
ATE261317T1
ATE261317T1 AT97938031T AT97938031T ATE261317T1 AT E261317 T1 ATE261317 T1 AT E261317T1 AT 97938031 T AT97938031 T AT 97938031T AT 97938031 T AT97938031 T AT 97938031T AT E261317 T1 ATE261317 T1 AT E261317T1
Authority
AT
Austria
Prior art keywords
radioactively labeled
labeled annexins
annexins
annexin
radiolabeled
Prior art date
Application number
AT97938031T
Other languages
English (en)
Inventor
Sudhakar Kasina
John M Reno
Alan R Fritzberg
Jonathan Tait
Original Assignee
Neorx Corp
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corp, Univ Washington filed Critical Neorx Corp
Application granted granted Critical
Publication of ATE261317T1 publication Critical patent/ATE261317T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Steroid Compounds (AREA)
  • Lubricants (AREA)
AT97938031T 1996-07-26 1997-07-24 Radioaktiv markierte annexine ATE261317T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/690,184 US5968477A (en) 1994-01-24 1996-07-26 Radiolabeled annexin conjugates with hexose and a chelator
PCT/US1997/012977 WO1998004294A2 (en) 1996-07-26 1997-07-24 Radiolabeled annexins

Publications (1)

Publication Number Publication Date
ATE261317T1 true ATE261317T1 (de) 2004-03-15

Family

ID=24771451

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938031T ATE261317T1 (de) 1996-07-26 1997-07-24 Radioaktiv markierte annexine

Country Status (7)

Country Link
US (5) US5968477A (de)
EP (2) EP1426062A3 (de)
JP (1) JP2001500116A (de)
AT (1) ATE261317T1 (de)
CA (1) CA2261902C (de)
DE (1) DE69728046T2 (de)
WO (1) WO1998004294A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
KR20010020443A (ko) * 1997-04-30 2001-03-15 캐서린 구 생체내 세포 치사를 이미지화시키는 방법
AU8388098A (en) * 1997-07-11 1999-02-08 Mount Sinai School Of Medicine Of The City University Of New York, The Assays for diagnosis of thrombophilic disease
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6323313B1 (en) 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
WO2002067857A2 (en) * 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
AU2002252105A1 (en) * 2001-02-21 2002-09-12 Imetrx, Inc. Methods and systems which use annexin for bioprofiling body lumen
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
WO2002080754A2 (en) * 2001-04-03 2002-10-17 Theseus Imaging Corporation Methods for using annexin for detecting cell death in vivo and treating associated conditions
US20050013778A1 (en) * 2001-04-03 2005-01-20 Theseus Imaging Corporation Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
CA2443314C (en) * 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
DE60231801D1 (de) 2001-04-23 2009-05-14 Mallinckrodt Inc Tc und re markierte radioaktive glycosylierte octreotid-derivate
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
US6982154B2 (en) * 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
WO2004013303A2 (en) * 2002-08-02 2004-02-12 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
AU2005221195B2 (en) * 2004-03-11 2011-05-19 Alavita Pharmaceuticals, Inc. Modified annexin proteins and methods for preventing thrombosis
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
DK1755642T3 (da) * 2004-04-15 2010-05-10 Athera Biotechnologies Ab Annexin V til forebyggelse af plaksprængning
EP1797106A1 (de) * 2004-09-07 2007-06-20 Triumf, operating as a joint venture by the Governors of the Universities of Alberta, Synthese von radioaktiv markierten zucker-metall-komplexen
US7874975B2 (en) * 2005-07-20 2011-01-25 Clear Vascular, Inc. Methods and compositions for treating luminal inflammatory disease
US9623129B2 (en) * 2005-09-26 2017-04-18 Snip Holdings, Inc. Methods and therapies for treating inflammatory conditions with exposed collagen
US7871623B2 (en) * 2005-12-21 2011-01-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for imaging pain and stress in vivo
WO2009070787A1 (en) * 2007-11-27 2009-06-04 The Regents Of The University Of California Methods for determining presence of vascular plaques using pretargeting reagent and ab-sn conjugates
US20100331819A1 (en) * 2009-06-24 2010-12-30 Abbott Cardiovascular Systems Inc. Drug Delivery System and Method of Treatment of Vascular Diseases Using Photodynamic Therapy
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
CN102875610A (zh) * 2012-09-19 2013-01-16 淮海工学院 一种制备2-乙酰氨基-2-脱氧-3,4,6-三乙酰-β-D-氯代吡喃葡糖的方法
EP3037820A1 (de) * 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Zellerkennungsverfahren und Reagenzien mit lösbarem Etikettierungsteil
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
WO2024106539A1 (ja) * 2022-11-18 2024-05-23 株式会社ボナック リガンドコンジュゲート物質及びそれを含む核酸並びにその用途

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US530950A (en) * 1894-12-18 School seat and desk
US4416865A (en) * 1973-02-20 1983-11-22 Research Corporation Radiopharmaceuticals for localization of thromboembolic disease
DE2616984C3 (de) 1976-04-17 1981-10-29 Behringwerke Ag, 3550 Marburg Verfahren zur Isolierung und Reinigung eines plazentenspezifischen Glycoproteins
DE2720704C2 (de) * 1977-05-07 1986-09-25 Behringwerke Ag, 3550 Marburg Neues Glycoprotein, Verfahren zu seiner Herstellung und seine Verwendung
US4195073A (en) 1977-10-27 1980-03-25 Hoffmann-La Roche Inc. Radioimmunoassay of alpha 1 fetoprotein
US4223002A (en) 1978-08-28 1980-09-16 Hoffmann-La Roche Inc. Isolation of alpha1 -fetoprotein
DE2952792A1 (de) * 1979-12-31 1981-07-02 Behringwerke Ag, 3550 Marburg Neues protein (pp(pfeil abwaerts)15(pfeil abwaerts)) mit immunsuppressiver wirkung
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
US4427646A (en) * 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
DE3228503A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Neues protein (pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)7(pfeil abwaerts)), verfahren zu seiner anreicherung und gewinnung sowie seine verwendung
US4558120A (en) * 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4507466A (en) * 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4568737A (en) * 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
US4673562A (en) * 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4571336A (en) * 1983-08-25 1986-02-18 Endorphin, Inc. Immune stimulation
DE3338480A1 (de) * 1983-10-22 1985-05-02 Behringwerke Ag, 3550 Marburg Neues protein pp(pfeil abwaerts)2(pfeil abwaerts)(pfeil abwaerts)0(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
DE3410694A1 (de) * 1984-03-23 1985-10-03 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)2(pfeil abwaerts)(pfeil abwaerts)1(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
DE3418888A1 (de) * 1984-05-21 1985-11-21 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
EP0163294A2 (de) 1984-06-01 1985-12-04 E.I. Du Pont De Nemours And Company Lösliches Kupfersalz enthaltende Zubereitungen, verwendbar bei der Herstellung von mit Technetium markierten radiodiagnostischen Agenzien
US4587329A (en) * 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
ES8702431A1 (es) * 1984-09-21 1986-12-16 Boehringer Ingelheim Int Procedimiento para preparar una proteina inhibidora de la coagulacion de la sangre
US5066788A (en) * 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4879224A (en) * 1985-01-10 1989-11-07 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
US4950646A (en) * 1985-01-10 1990-08-21 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human lipocortin-like polypeptides
US5081019A (en) * 1985-01-10 1992-01-14 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lipocortin-like polypeptides
US4874743A (en) * 1985-01-10 1989-10-17 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5120526A (en) * 1985-01-14 1992-06-09 Neorx Corporation Method of producing metal radionuclide labeled proteins for diagnosis and therapy
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
US4746505A (en) * 1985-04-26 1988-05-24 President And Fellows Of Harvard College Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands
US4775638A (en) * 1985-05-08 1988-10-04 Centocor, Inc. Single vial technique for radiolabeling protein
US4827483A (en) 1985-08-12 1989-05-02 Hitachi, Ltd. Semiconductor laser device and method of fabricating the same
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
US5055561A (en) * 1985-11-19 1991-10-08 The Johns Hopkins University Protein label and drug delivery system
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
US5279811A (en) * 1987-02-18 1994-01-18 The Du Pont Merck Pharmaceutical Company Ester-substituted diaminedithiols and radiolabeled complexes thereof
JP2660514B2 (ja) 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
US4965392A (en) * 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
PT87083B (pt) 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US5489425A (en) * 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
DE3724726A1 (de) * 1987-07-25 1989-02-02 Behringwerke Ag Verfahren zur reinigung des plazentaren gewebeproteins pp4
DE3737239A1 (de) 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
US5320950A (en) * 1987-11-03 1994-06-14 Behringwerke Aktiengesellschaft DNA encoding anticoagulative protein PP4-X, and its preparation and use
DE3737237A1 (de) * 1987-11-03 1989-05-18 Behringwerke Ag Anticoagulatorisches protein pp4-x, seine herstellung und verwendung
CH676362A5 (de) * 1987-12-24 1991-01-15 Nippon Shinyaku Co Ltd
EP0322876A3 (de) * 1987-12-29 1990-09-05 Nihon Medi-Physics Co., Ltd. Chelierende Verbindungen und deren Verwendung
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
EP0329184A3 (de) * 1988-02-19 1990-05-23 Neorx Corporation Antimere und antimere Konjugation
DE68923107T2 (de) * 1988-02-26 1996-01-18 Biogen Inc DNA-Sequenzen, rekombinante DNA-Moleküle und Verfahren zur Herstellung von Lipocortin III, IV, V, und VI.
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
DE3810331A1 (de) 1988-03-26 1989-10-05 Boehringer Ingelheim Int Monoklonale vac-antikoerper
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5075099A (en) * 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5179081A (en) * 1988-07-21 1993-01-12 Kowa Co., Ltd. Method of treatment using an anticoagulant polypeptide
JP2701047B2 (ja) * 1988-07-21 1998-01-21 興和株式会社 抗血液凝固作用を有するポリペプチド
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
DE3900649A1 (de) 1989-01-11 1990-07-12 Boehringer Mannheim Gmbh Verfahren zur abloesung eines analyten von seinem bindeprotein
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5164176A (en) * 1989-06-16 1992-11-17 Neorx Corporation Radionuclide metal chelates for the radiolabeling of proteins
US5250666A (en) * 1989-06-16 1993-10-05 Neorx Corporation Radionuclide metal chelates for the radiolabeling of proteins
DE4021979A1 (de) * 1989-07-15 1991-01-31 Boehringer Ingelheim Int Verfahren zur reinigung von annexinen
DE4022010A1 (de) * 1989-07-15 1991-01-17 Boehringer Ingelheim Int Ein antikoagulanz enthaltendes mittel
US5162505A (en) * 1989-09-19 1992-11-10 Centocor Proteins modified with positively charged carriers and compositions prepared therefrom
US5288623A (en) * 1989-10-26 1994-02-22 Chisso Corporation Process for secretory production of a calcium-binding protein
DE3937607A1 (de) * 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
US5118610A (en) * 1989-11-30 1992-06-02 Board Of Regents, The University Of Texas System Techniques for detecting insect contamination of foodstuffs
ATE101596T1 (de) * 1989-12-12 1994-03-15 Amersham Int Plc Phenyldiaminodithiolderivate.
US5026913A (en) * 1989-12-12 1991-06-25 Medi-Physics, Inc. Hydrocarbylphenyl diaminodithiol derivatives
US5080884A (en) * 1989-12-12 1992-01-14 Medi-Physics, Inc. Hydrocarbylphenyl diaminodithiol radionuclide complexes and their use in imaging
DE3942081A1 (de) * 1989-12-20 1991-06-27 Behringwerke Ag Mittel zur verbesserung der wiederfindung von annexinen
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
CA2070647C (en) * 1989-12-27 2001-04-10 Christiaan Reutelingsperger Use of an anticoagulant as a diagnostic agent
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE4012341A1 (de) * 1990-04-18 1991-10-24 Behringwerke Ag Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung
US5091550A (en) 1990-04-20 1992-02-25 Ciba-Geigy Corporation 5,5-bis (perfluoroalkylheteromethyl)-2-hydroxy-2-oxo-1,3,2-dioxaphosphorinanes, derived acyclic phosphorus acids and salts or esters thereof
US5079346A (en) * 1990-05-01 1992-01-07 Trustees Of The University Of Pennsylvania Gallium-labelled imaging agents
US5116598A (en) * 1990-10-29 1992-05-26 Mallinckrodt Medical, Inc. N4 technetium-99 m complexes for use as radiopharmaceuticals
US5104638A (en) * 1990-10-29 1992-04-14 Mallinckrodt Medical, Inc. Method of making a radiopharmaceutical complex from a kit
US5552525A (en) * 1991-02-08 1996-09-03 Diatech Inc. Technetium-99m labeled peptides for imaging inflammation
DE69230525T2 (de) * 1991-02-08 2000-06-21 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
US5645815A (en) * 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
EP0538459A4 (en) * 1991-05-09 1993-06-16 The Board Of Regents Of The University Of Washington Phospholipid-targeted thrombolytic agents
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5314992A (en) * 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
US5371184A (en) * 1992-02-05 1994-12-06 Mallinckrodt Medical, Inc. Radiolabelled peptide compounds
US5616690A (en) * 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
NL9201722A (nl) * 1992-10-05 1994-05-02 Stichting Tech Wetenschapp Farmaceutische samenstelling voor de plaatsgebonden afgifte van een stolsel oplossend eiwit en werkwijze voor de bereiding daarvan.
US5380646A (en) * 1992-10-19 1995-01-10 Temple University Of The Commonwealth System Of Higher Education Thrombus detection using radiolabelled disintegrins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US20030220233A1 (en) * 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
WO1995034315A1 (en) * 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
EP0799050B1 (de) * 1994-12-07 2004-08-11 Neorx Corporation Radioaktivmarkierte annexin-galaktose-cluster konjugate
US5886143A (en) * 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof

Also Published As

Publication number Publication date
CA2261902A1 (en) 1998-02-05
WO1998004294A2 (en) 1998-02-05
CA2261902C (en) 2008-04-22
JP2001500116A (ja) 2001-01-09
WO1998004294A3 (en) 1998-06-04
US5968477A (en) 1999-10-19
US6171577B1 (en) 2001-01-09
US7744853B2 (en) 2010-06-29
DE69728046D1 (de) 2004-04-15
EP0918547B1 (de) 2004-03-10
US20060029545A1 (en) 2006-02-09
EP0918547A2 (de) 1999-06-02
EP1426062A3 (de) 2005-04-06
EP1426062A2 (de) 2004-06-09
US20020137672A1 (en) 2002-09-26
US20110269943A1 (en) 2011-11-03
DE69728046T2 (de) 2005-03-17

Similar Documents

Publication Publication Date Title
ATE261317T1 (de) Radioaktiv markierte annexine
DE19581655T1 (de) Bandscheibenimplantat
FR2709949B1 (fr) Prothèse de disque intervertébral.
DK0954588T3 (da) OB fusionsprotein-sammensætninger og fremgangsmåder
FR2707480B1 (fr) Prothèse discale intervertébrale.
DE69715348D1 (de) Hüftgelenkprothese
FR2751867B1 (fr) Prothese collerette
PT921808E (pt) Formulacoes peptidicas nao aquosas polares aproticas
NO983235L (no) Fikstur og protese innbefattende samme
DE69726844D1 (de) Künstliche zwischenwirbelscheibe
DE69129454D1 (de) Kniescheibenprothese
DE69114050D1 (de) Kugelgelenk für Prothese.
DE69715175D1 (de) Bilderzeugung
BR9701155A (pt) Junta homocinética fixa de esferas
ATE237366T1 (de) Radioaktiv-markierte annexine
NO983828D0 (no) Kontrastmiddel
DE69602936D1 (de) Detektor-Objektivlinse
DE59706327D1 (de) Feinfokussiertisch
NO940115D0 (no) Kontrastmidler for roentgen- og magnettomografisk avbildning
DE69713655D1 (de) Drehbucheditor
FR2749162B1 (fr) Prothese cotyloidienne
NO951197L (no) Integrert freserör og lagersammenstilling
DE69530841D1 (de) Radioaktivmarkierte annexin-galaktose konjugate
IT1290530B1 (it) Ferro da stiro e procedimento di assemblaggio di un tale ferro
DE69709575D1 (de) Magnetischer Aufzeichnungsträger und diesen Träger verwendendes magnetisches Aufzeichnungssystem

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties